[ad_1]

Clay Siegall, the former CEO of Seattle-area biotech behemoth Seagen before stepping down last year amid claims of domestic violence, is returning to the city to manage a merged biotech firm.

Siegall, who was not charged following his arrest in 2022 and has denied any wrongdoing, will be the chairman and CEO of Morphimmune and Immunome, which will retain the Immunome moniker.

Immunome and Morphimmune, where Siegall has been CEO since March, announced the merger and Siegall’s role on Thursday. The united company’s headquarters will be in Seattle.

Siegall, the co-founder of Bothell-based cancer therapy company Seagen, was once dubbed Washington’s highest-paid CEO. Pfizer agreed to buy Seagen for $43 billion in March. David Epstein took over as CEO in November.

Siegall left Seagen in May 2022 following charges that he abused his then-wife in front of two friends at the couple’s Woodway house. According to a prosecutors’ memo obtained by The Seattle Times through a public records request, prosecutors declined to prosecute Siegall in December, citing evidence concerns such as “insurmountable inconsistencies” in witness, suspect, and alleged victim testimonies.

Siegall migrated to Indiana, where Morphimmune is based. On Thursday, the firm announced a merger with Immunome, situated in Exton, Pa.

“This is the first step towards establishing a preeminent oncology company,” Siegall said in a merger announcement.

The size of the all-stock transaction, which is anticipated to finalize later this year, was not disclosed by the firms. Immunome will maintain research labs in Exton and West Lafayette.

In addition to the agreement, the businesses announced a $125 million commitment to develop three targeted cancer treatments within 18 months of the agreement’s completion.

[ad_2]

Source link